Vir Biotechnology recently announced it will present data from its Phase 2 SOLSTICE trial of the tobevibart-elebsiran combination for chronic hepatitis delta at the EASL Congress 2026 in Barcelona, ...
Detailed price information for Assembly Biosciences (ASMB-Q) from The Globe and Mail including charting and trades.
The US Food and Drug Administration (FDA) has granted accelerated approval for Gilead Sciences’ (Nasdaq: GILD) Hepcludex (bulevirtide-gmod) 8.5mg for the treatment of adults living with chronic ...
Gilead Sciences received accelerated approval for a chronic hepatitis delta virus treatment from the Food and Drug Administration. The FDA said the Hepcludex treatment, known also as bulevirtide-gmod, ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated ...
Food and Drug Administration said on Friday it approved Gilead Sciences' drug for a rare and deadly liver infection that ...
The U.S. Food and Drug Administration said on Friday it approved Gilead Sciences' drug for a rare and deadly liver ...
Phase 2 study in cholestatic liver diseases, focused on PBC and PSC, anticipated to initiate in Q1 2027 -- Builds on completed Phase 1a study and ongoing development in HDV - SOUTH SAN FRANCISCO, ...
Phase 2 study in cholestatic liver diseases, focused on PBC and PSC, anticipated to initiate in Q1 2027 –– Builds on completed Phase 1a study ...
Phase 2 study in cholestatic liver diseases, focused on PBC and PSC, anticipated to initiate in Q1 2027 – – Builds on completed Phase 1a study and ongoing development in HDV – Javascript is required ...
Tech stocks in a dividend ETF might sound tempting -- but think carefully about your strategy and risk tolerance.
Not all high-yield ETFs are built the same. In the case of the two major high-dividend yield funds from iShares and Vanguard, there's a clear winner.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results